Article Sidebar
Published:
Mar 12, 2024Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of calcitriol in the treatment of patients with renal osteodystrophy
Abstract
Purpose: To investigate the efficacy and prognosis of calcitriol in patients with renal osteodystrophy (ROD).
Methods: 60 patients with ROD admitted to The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, China between June 2020 and June 2021 were randomly grouped into control (n = 30) and study groups (n = 30). Patients in control group received routine management study group was treated with routine management plus calcitriol. The treatment duration was six months. Serological markers (parathyroid hormone (PTH), calcium (Ca), and phosphorus (Pi)), renal function indices (blood creatinine (SCr), urea nitrogen (BUN), and alkaline phosphatase (ALP)), as well as patients’ skeletal conditions of the spine, pelvis, and extremities were investigated. Additionally, postoperative complications and clinical efficacy were also evaluated.
Results: Study group showed significant improvement in serological markers compared to control group (p < 0.05). Also, study group had significantly reduced SCr, BUN, and ALP levels (p < 0.05) compared to control group. There was significantly reduced incidence of complications and better skeletal conditions in study group compared to control group (p < 0.05).
Conclusion: Calcitriol effectively mitigates blood-bone mechanism dysfunction and reduces the occurrence of complications in patients with ROD. However, factors such as Scr, Hb, and blood pressure affect the clinical efficacy of calcitriol on renal bone disease by mechanisms that will be investigated in the future.
